Why will it never be known if convalescent plasma is effective for COVID-19 | Zendy

Manuel Rojas | Zendy; JuanManuel Anaya | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Why will it never be known if convalescent plasma is effective for COVID-19

Author(s) -

Manuel Rojas,

JuanManuel Anaya

Publication year - 2020

Publication title -

journal of translational autoimmunity

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.199

H-Index - 3

ISSN - 2589-9090

DOI - 10.1016/j.jtauto.2020.100069

Subject(s) - convalescent plasma , covid-19 , randomized controlled trial , medicine , clinical endpoint , intensive care medicine , virology , outbreak , disease , infectious disease (medical specialty)

High expectations have been set around convalescent plasma (CP) for the treatment of COVID-19. However, none of the randomized controlled trials (RCTs) conducted so far have reached their primary endpoints. Herein we report that RCTs of CP disclose a high methodological variability in inclusion criteria, outcomes, appropriate selection of donors, dosage, concentration of neutralizing antibodies and times of transfusion. Therefore, at this time there is insufficient evidence to recommend for or against the use of CP as a treatment for COVID-19.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research